Scapa Healthcare will buy the Systagenix facility in Gargrave, England, from Acelity, Scapa announced this week.
The deal includes manufacturing operations, sterilization services, warehouse facilities, R&D and regulatory support functions located in Gargrave. Scapa and Acelity will also enter into a long-term manufacturing and supply agreement for the advanced wound dressings offered by KCI, an Acelity company, manufactured in Gargrave. Financial terms were not disclosed.
The 335,000-square-foot Gargrave site will significantly enhance Scapa’s capabilities, services and footprint in advanced wound care, consumer wellness and wearable medical devices, according to a company statement. Scapa, based in Ashton-on-Lyne, England, makes skin-friendly adhesives.
“At Scapa Healthcare, our goal is to be the trusted strategic outsource partner of choice for our customers,” said company president Joe Davin in the statement. “This technology transfer is in line with our growth strategy, and we are excited about the opportunities this facility brings as we continue to expand our portfolio of turn-key solutions.”
The manufacturing supply agreement is set to take effect in early October. Until then, Acelity will continue to manage and operate the business of Systagenix Wound Management Manufacturing.
Scapa is also building a medical device factory in Knox County, Tenn. The new facility will be 152,000 sq. ft and will double the company’s footprint in the Knoxville, Tenn. area and will integrate the three existing buildings in Knoxville into a single operations site. The new facility is also designed to improve workflow and materials movement across the cleanroom, printing, packaging and warehouse departments. Scapa expects construction to be complete by the end of 2018.
